

Taibah University Journal of Taibah University Medical Sciences

www.sciencedirect.com

Original Article

# Prevalence and patterns of bone mineral density disorders among women in Buraidah, KSA

Abdulrhman Aldukhayel, SBFM

Department of Family & Community Medicine, College of Medicine, Qassim University, Buraidah, KSA

Received 29 April 2022; revised 9 September 2022; accepted 16 September 2022; Available online 8 October 2022

# الملخص

أهداف البحث: تسبب اضطرابات كثافة العظام عبنا صحيا واجتماعيا على الأفراد والمجتمعات. هدفت هذه الدراسة إلى تقدير انتشار وتحديد أنماط اضطرابات كثافة العظام بين النساء في مدينة بريدة بالمملكة العربية السعودية.

**طرق البحث:** أجريت دراسة مقطعية بين النساء اللواتي حضرن لفحص كثافة العظام في مركز صحي الأفق ببريدة. تم تضمين ما مجموعه ٣٤٢ امرأة في الدراسة. تم استخدام جهاز قياس امتصاص الأشعة السينية ذات الطاقة المزدوجة (دكسا) لقياس كثافة العظام وتم تحديد التشخيص بناءً على معايير منظمة الصحة العالمية: طبيعي= درجة ت أكبر من - ١ ، لين العظام = درجة ت المكافئة بالصحة. ٢٥ . مما شم جمع البيانات المختلفة الاجتماعية والديمو غرافية والمتغيرات المتعلقة بالصحة.

النتائج: كان متوسط عمر المشاركين ٦١.٢ ± ٧.٥٤ سنة. بلغ معدل الانتشار العام لاضطرابات كثافة العظام ٧٦٪ ، بينما بلغ انتشار لين العظام و هشاشة العظام ٢٦٪ و ٣٤٪ على التوالي. تأثر العمود الفقري أكثر من عنق عظم الفخذ.

**الاستنتاجات:** ارتفاع معدل انتشار اضطرابات كثافة العظام بين النساء في المملكة العربية السعودية يدعو إلى إنشاء وتعزيز برامج الوقاية من هشاشة العظام لضمان الشيخوخة الصحية بين النساء. هناك حاجة لدراسات مجتمعية واسعة النطاق لتقدير عبء اضطرابات كثافة المعادن بالعظام في المجتمع بدقة.

الكلمات المفتاحية: كثافة العظام؛ ديكسا؛ قلَّة النسيج العظمي؛ هشاشة العظام؛ المملكة العربية السعودية

# Abstract

**Objectives:** Bone mineral density (BMD) disorders are disorders of bone mineralization in which bone density is reduced (T score <-1). BMD causes health and

E-mail: m\_dkhiel@qu.edu.sa

Peer review under responsibility of Taibah University.

ELSEVIER Production and hosting by Elsevier

social burdens on individuals and communities. This study estimated the prevalence and determined the patterns of BMD disorders among women in Buraidah, KSA.

**Methods:** A cross-sectional study was conducted in 342 women visiting the DEXA Scanning Center in Buraidah. Dual-energy X-ray absorptiometry (DEXA) scan was used to measure the BMD, and cutoffs were defined based on World Health Organization criteria: normal = T score >-1, osteopenia = T score <-1 to >-2.5, and osteoporosis = T score  $\leq$ -2.5. Sociodemographic and health-related data were collected. Logistic regression was used to measure the association of various participant characteristics with BMD disorders.

**Results:** The mean age of the participants was  $61.2 \pm 7.54$  years. The overall prevalence of BMD disorders was 76%, of whom 42% had osteopenia, 24% had both osteoporosis and osteopenia, and 10% had osteoporosis. Body mass index, menopause, hypertension, oral hypoglycemics, and calcium supplementation were significant predictors of BMD disorders.

**Conclusions:** The high prevalence of BMD disorders among women in KSA necessitates establishing and strengthening osteoporosis prevention programs to ensure healthy aging among women in KSA. Large-scale community-based studies are needed to accurately estimate the burden and risk factors of BMD disorders in the community.

Keywords: Bone mineral density; DEXA; KSA; Osteopenia; Osteoporosis

© 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1658-3612 © 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). https://doi.org/10.1016/j.jtumed.2022.09.014





## Introduction

Osteoporosis and osteopenia are progressive bone mineral density (BMD) disorders, which are caused by a decline in bone mass and architectural changes in bone structure. These changes result in reduced bone density and bone quality. Consequently, these disorders increase the risk of fragility fractures among the affected individuals.<sup>1</sup> Osteoporosis is defined by the World Health Organization (WHO) as a "decline in BMD mass by more than 2.5 standard deviations (SDs)," whereas osteopenia is defined as a "decline in BMD mass 1.0–2.5 SD."<sup>2</sup>

Osteoporosis and associated factures are important health issues globally, especially among nations with a higher proportion of elderly individuals.<sup>3,4</sup> Osteoporosis affects about 200 million women globally and causes about 8.9 million fractures annually.<sup>5,6</sup> It is estimated that about 188,000 deaths and 5.2 million Disability Adjusted Life Years (DAYLs) are attributed to low BMD globally.<sup>7</sup> In the United states alone, it was estimated that about 2 million fractures were due to osteoporosis in 2005, which cost about 17 billion US dollars.<sup>8</sup> The number of fractures and cost are estimated to increase by 50% in 2025.

KSA has seen an increase in life expectancy and thus an increasing proportion of elderly individuals in the population. Studies from various parts of KSA have reported varying prevalence of osteoporosis among females. A systematic review by Sadat et al.,<sup>10</sup> which included studies until 2011, reported a prevalence of osteopenia and osteoporosis of 37% and 34%, respectively.<sup>9</sup> Studies from Arar found a prevalence of osteopenia of 36% in 2018, whereas another study in 2014 from the Northern part of KSA found a prevalence of osteoporosis of 18% in women.<sup>11</sup> In Taif, the prevalence of osteoporosis was 26% in 2019.<sup>12</sup> A community-based study from Rivadh in 2014 reported a prevalence of low BMD (T score <-1) of 58.5%.<sup>13</sup> In KSA, about 174,000 fractures annually are attributed to osteoporosis with an estimated direct cost of 636 million US dollars in 2019.<sup>14</sup>

Females are affected more than males. In women, estrogen helps maintain the resorptive capacities of the osteoclasts.<sup>15</sup> The reduction in estrogen after menopause among women increases the risk of osteoporosis and osteopenia. Therefore, these are common conditions in elderly women; however, younger women are also affected by BMD disorders although to a lesser extent.<sup>16</sup> In males, testosterone regulates the mineral deposition in bones, which declines slowly with age; therefore, the risk of osteoporosis is lower in males.<sup>17</sup>

Bone disorders are associated with health, personal, social, and financial consequences for the individual, family, and community at large. KSA is undergoing a demographic transition in which the elder population is increasing, which may add to the ever-increasing health and economic burdens of osteoporosis. The high prevalence of BMD disorders among women in KSA necessitates estimating the burden of osteoporosis in this country so that preventive and curative services can be tailored according to the needs. Furthermore, the health care system of KSA is undergoing a transition in which autonomy is transferred to regional health clusters to allocate resources according to the local needs. Therefore, it is necessary to have local data on the prevalence and patterns of osteoporosis in the Qassim region where no such study has been conducted.

To this end, this study assessed the prevalence, patterns, and risk factors of BMD disorders in Qassim, KSA.

# Materials and Methods

#### Study design and setting

This was an institution-based cross-sectional study among women conducted at the Qassim Regional DEXA Screening Center in Buraidah. The Qassim region is located in the central part of KSA with an estimated total population of about 1.4 million people. The region has the largest date palm fields in the country. The terrain is mainly desert with extreme summers. The osteoporosis screening center of Buraidah is the only center where patients are referred from all across the region.

#### Sample size

Sample size was calculated using the WHO manual for sample size calculation. Previous studies in KSA have reported that the prevalence of BMD disorders ranging from 18% to 63.2%. The current study used 63.2% to calculate the sample, as this study was conducted in a referral DEXA scanning center.<sup>18</sup> The formula for estimation of population proportions was used to calculate sample size. At a 95% confidence level and a margin of error of 5%, the required sample size was 358. However, due to time and resource constraints, data were collected from 343 women.

## Sampling procedure

Female who visited the DEXA Scanning Center Buraidah were recruited as study participants. Those who had a previously confirmed diagnosis of osteoporosis were excluded from the study. Women were recruited consecutively who visited the DEXA center from October 2020 until March 2021. Data on sociodemographic and health-related variables such as age, menopause, history of fragility fracture, presence of chorionic diseases, physical activity, and medication history was collected using a structured questionnaire by a trained nurse in Arabic language.

#### Dual-energy X-ray absorptiometry scanning procedure

#### Outcome assessment

Bone mineral densitometry was performed with dualenergy X-ray absorptiometry (DEXA) using the Horizon<sup>TM</sup> DXA System (Hologic, Inc., Bedford, MA, USA). Three sites were scanned: the lumbar spine and necks of the left and right femur. The scanner provides standardized T scores of BMD based on reference population. Z scores were interpreted according to WHO classification: normal = T score >-1, osteopenia = T score <-1 to >-2.5 and osteoporosis = T score  $\leq -2.5$ .<sup>2</sup> BMD disorders in this study included either or both osteopenia and osteoporosis.

# Statistical analyses

Data were entered and analyzed using SPSS version 21.0. Frequency and proportions of categorical variables and means with standard deviations (SDs) were calculated for continuous variables. The prevalence of BMD disorders were calculated by creating a composite variable combining the results from all three sites. The composite variable was coded as 0 =normal and 1 =BMD disorder present. The patterns of BMD disorders were determined based on the type and site. The chi square or Fisher's exact test was applied to assess the distribution of BMD disorders with respect to the patients' sociodemographic characteristics and medical history. Logistic regression analysis was used to assess the risk factors of BMD disorders. All of the predictor variables included in the regression analysis were coded as 0 = No and 1 = Yes. First, univariate logistic regression analyses were conducted. Variables that were either significant or clinically important were included in the multivariate regression analysis. Multivariate logistic regression analysis was done to adjust for the confounding effects of variables on their associations with outcome variables. The variables in the final multivariate model were retained based on their significance and effect on the  $-2 \log$  likelihood ratio. The adjusted odds ratio (OR) and associated 95% confidence intervals were calculated. A pvalue <0.05 was considered statistically significant.

# Results

#### Sample characteristics

A total of 343 women were included in the analysis. The mean age of the participants was  $61.2 (\pm 7.54)$  years. The majority (90%) of the women had reached menopause, and the mean age of menopause was 50 years. The family history of fragility fracture was positive in 3.5% of the participants, whereas 1.7% had fragility fracture in the past. Only 30% of the participants performed physical activity >150 min/ week. Three-fourths (76%) of the women had chronic diseases, of which the most common was diabetes mellitus (DM) (70%), followed by hypertension (64%). About 87% of the participants were on medication currently. Oral hypoglycemic (49%) and antihypertensive (48%) were most common medications followed by vitamin D and proton pump inhibitors (Table 1).

#### Prevalence of BMD disorders

Figure 1 shows the prevalence of BMD disorders. Threefourths (76%) of the women had BMD disorders. Osteopenia was the most common disorder and present in 42% of the participants. Osteoporosis was present in 10% of participants, whereas both osteopenia and osteoporosis were present in 24% of the women. The overall prevalence of osteoporosis was 34%, whereas the overall prevalence of osteopenia was 66%.

# Patterns of BMD disorders

Table 2 presents the patterns of BMD disorders. The prevalence pf BMD disorder was higher in the spine

| l | able        | 1: Socio | demogra   | phic ch | aracter  | istics of | of wom | en visiting | g a |
|---|-------------|----------|-----------|---------|----------|-----------|--------|-------------|-----|
| Ľ | <b>DEXA</b> | scannii  | ng center | in Bur  | aidah, I | KSA (I    | n = 34 | 13).        |     |

| Characteristics                             | n (%)            |
|---|------------------|
| Age (years)                                 |                  |
| Mean (SD)                                   | 61.2 (7.54)      |
| Menopause                                   |                  |
| No  | 30 (8.7)         |
| Yes   | 313 (91.3)       |
| Age of menopause $(n = 313)$                |                  |
| Mean (SD)                                   | 50.0 (3.27)      |
| Time since menopause $(n = 313)$            |                  |
| $\leq 10$ years                             | 120 (38.3)       |
| >10 years                                   | 193 (61.7)       |
| History of fragility fracture               |                  |
| No  | 331 (96.5)       |
| Yes   | 12 (3.5)         |
| Family history of fragility fracture (after | age of 50 years) |
| No  | 337 (98.3)       |
| Yes   | 6 (1.7)          |
| Physical activity                           |                  |
| No  | 225 (65.6)       |
| Yes, <150 min/week                          | 16 (4.7)         |
| Yes, >150 min/week                          | 102 (29.7)       |
| Family history of osteoporosis              | · · ·            |
| No  | 251 (73.2)       |
| Unknown                                     | 87 (25.4)        |
| Yes   | 5 (1.5)          |
| Chronic disease                             |                  |
| No  | 81 (23.6)        |
| Yes   | 262 (76.4)       |
| Chronic diseases $(n = 262)$                |                  |
| Diabetes Mellitus                           | 183 (69.8)       |
| Hypertension                                | 169 (64.5)       |
| Hypothyroidism                              | 51 (19.5)        |
| Hyperthyroidism                             | 4 (1.5)          |
| Number of chronic diseases $(n = 262)$      |                  |
| 1   | 135 (51.4)       |
| 2   | 109 (41.6)       |
| 3   | 18 (6.9)         |
| Current medication                          |                  |
| No  | 39 (11.4)        |
| Yes   | 304 (88.6)       |
| Type of medicine                            |                  |
| Oral hypoglycemic                           | 169 (49.3)       |
| Insulin                                     | 23 (6.7)         |
| Antihypertensive                            | 164 (47.8)       |
| Thyroxine                                   | 52 (15.2)        |
| Vitamin D                                   | 103 (30.0)       |
| Calcium                                     | 64 (18.7)        |
| PPIs  | 73 (21.3)        |
| Oral cortisone                              | 2 (0.6)          |

(67.7%) compared to the right and left femur (49%) and (50%). Osteoporosis was highest in the spine (31%) compared to the right femur (13.1%) and left femur (9.0%). On the other hand, osteopenia was higher in the left femur 40.5% but lowest in the spine (37%). In 20% of the participants, osteoporosis was present in one site only, whereas 7% and 6% had osteoporosis on two and three sites, respectively. Single site osteopenia was present in 27%, whereas two sites and three sites osteopenia were present in 27% and 12% of the participants, respectively. The distribution of BMD disorders with respect to various characteristics of participants are presented in Table 3. The



Figure 1: Prevalence of BMD disorders among women in Buraidah, KSA.

| Table 2 | 2: Patterns | of BMD     | disorder  | among  | women | visiting a |
|---------|-------------|------------|-----------|--------|-------|------------|
| DEXA    | scanning o  | enter in B | Buraidah, | KSA (n | = 343 | ).         |

| Variable                 | n (%)      |
|--------------------------|------------|
| Spine BMD disorder       |            |
| No                       | 111 (32.4) |
| Yes                      | 232 (67.6) |
| BMD disorder right femur |            |
| No                       | 168 (49.0) |
| Yes                      | 175 (51.0) |
| BMD disorder left femur  |            |
| No                       | 173 (50.4) |
| Yes                      | 170 (49.6) |
| BMD pattern spine        |            |
| Normal                   | 111 (32.4) |
| Osteopenia               | 127 (37.0) |
| Osteoporosis             | 105 (30.6) |
| BMD pattern right femur  |            |
| Normal                   | 168 (49.0) |
| Osteopenia               | 130 (37.9) |
| Osteoporosis             | 45 (13.1)  |
| BMD pattern left femur   |            |
| Normal                   | 173 (50.4) |
| Osteopenia               | 139 (40.5) |
| Osteoporosis             | 31 (9.0)   |
| Pattern of osteopenia    |            |
| Normal                   | 117 (34.1) |
| One site                 | 93 (27.1)  |
| Two sites                | 93 (27.1)  |
| Three sites              | 40 (11.7)  |
| Pattern of osteoporosis  |            |
| Normal                   | 228 (66.5) |
| One site                 | 70 (20.4)  |
| Two sites                | 24 (7.0)   |
| Three sites              | 21 (6.1)   |

mean age (62.1 [7.6] years) of the participants with BMD disorders was significantly higher compared to those without the disorder (58.5 [6.7] years) (p < 0.001). The body mass index (BMI) was significantly lower in those with BMD disorders (p < 0.001). There was a significant

Table 3: Patterns of BMD disorder with respect to sociodemographic and medical history of women visiting a DEXA scanning center in Buraidah, KSA (n = 343).

| $\begin{array}{c c c c c c c c c c c c c c c c c c c $   | Variables                          | BMD        | BMD                      | p-value                    |
|--|------------------------------------|------------|--------------------------|----------------------------|
| $\begin{array}{ c c c c c c c c c c c c c c c c c c c$   |                                    | disorder   | disorder                 |                            |
| n (%)n (%)Age  |                                    | present    | absent                   |                            |
| Age<br>Mean (SD) $62.1 (7.6)$ $58.5 (6.7)$ $<0.001^*$ BMIMean (SD) $31.4 (5.8)$ $34.2 (4.6)$ $<0.001^*$ Menopause $14 (46.7)$ $16 (53.3)$ $<0.001^*$ No $14 (46.7)$ $16 (53.3)$ $<0.001^*$ Age at menopause (n = $313)$ $=$ $<0.001^*$ Sea to menopause (n = $313)$ $<0.001^*$ $>10 (923)$ $0.053^*$ Sine since menopause (n = $313)$ $<0.001^*$ $>10 (923)$ $<0.001^*$ $\leq 10 years$ $80 (66.7)$ $40 (33.3)$ $<0.001^*$ > 10 years $166 (86.0)$ $27 (14.0)$ $0.635^c$ No $256 (76.0)$ $81 (24.0)$ $0.635^c$ Yes $6 (50.0)$ $6 (50.0)$ $6 (50.0)$ Family history of fragility fracture (after age of 50 years)No $256 (76.0)$ $81 (24.0)$ No $256 (76.0)$ $81 (24.0)$ $0.635^c$ Yes $4 (66.7)$ $2 (33.3)$ $2 (12.5)$ YesPhysical activity $No$ $27 (70.6)$ $30 (29.4)$ $0.224$ Yes, <150 min/week $174 (77.3)$ $51 (22.7)$ YesFamily history of osteopers $No$ $187 (74.5)$ $64 (25.5)$ $0.754^c$ Unknown $69 (79.3)$ $18 (20.7)$ Yes $130 (81.3)$ $30 (18.8)$ $0.028^*$ Yes $196 (74.8)$ $66 (25.2)$ $1000$ $1000$ $1000$ Chronic disease $No$ $130 (81.3)$ $30 (18.8)$ $0.028^*$ Yes $130 (71.0)$ $51 (29.3)$ $0.028^*$ $123 (70.7)$ <t< th=""><th></th><th>n (%)</th><th>n (%)</th><th></th></t<>   |                                    | n (%)      | n (%)                    |                            |
| Mean (SD) $62.1$ (7.6) $58.5$ ( $6.7$ ) $<0.001^*$ BMIMean (SD) $31.4$ ( $5.8$ ) $34.2$ ( $4.6$ ) $<0.001^*$ MenopauseNo $14$ ( $46.7$ ) $16$ ( $53.3$ ) $<0.001^*$ Yes $246$ ( $78.6$ ) $67$ ( $21.4$ ) $Age$ at menopause ( $n = 313$ ) $<1001^*$ Age at menopause ( $n = 313$ ) $<10$ ( $33.3$ ) $<0.001^*$ ><br>><br>> 10 years80 ( $66.7$ ) $40$ ( $33.3$ ) $<0.001^*$ ><br>> 10 years166 ( $86.0$ )27 ( $14.0$ )History of fragility fracture $No$ $254$ ( $76.7$ ) $77$ ( $23.3$ ) $0.034^*$ Yes6 ( $50.0$ )6 ( $50.0$ ) $6$ ( $50.0$ )Family history of fragility fracture (after age of 50 years) $No$ No256 ( $76.0$ )81 ( $24.0$ ) $0.635^c$ Yes $4$ ( $66.7$ ) $2$ ( $33.3$ )Physical activityNo72 ( $70.6$ ) $30$ ( $29.4$ ) $0.224$ Yes $4$ ( $66.7$ ) $2$ ( $12.5$ )Yes $75^c$ Yes $4$ ( $66.7$ ) $2$ ( $12.5$ )YesNo187 ( $74.5$ ) $64$ ( $25.5$ ) $0.754^c$ Unknown $69$ ( $79.3$ )18 ( $20.7$ )Yes $4$ ( $80.0$ ) $120.0$ Chronic diseaseNo $130$ ( $81.3$ ) $30$ ( $18.8$ ) $0.028^*$ No $130$ ( $81.3$ ) $30$ ( $18.8$ ) $0.025^*$ Yes $130$ ( $81.3$ ) $30$ ( $18.8$ ) $0.025^*$ Yes $130$ ( $81.3$ ) $30$ ( $18.9$ ) $0.025^*$ Yes $130$ ( $81.3$ ) $30$ ( $18.9$ ) $0.025^*$ Yes $130$  | Age                                |            |                          |                            |
| BMI<br>Mean (SD) 31.4 (5.8) 34.2 (4.6) <0.001*<br>Menopause<br>No 14 (46.7) 16 (53.3) <0.001*<br>Yes 246 (78.6) 67 (21.4)<br>Age at menopause (n = 313)<br>$\leq 10$ years 246 (78.6) 67 (21.4)<br>Mean (SD) 49.8 (3.0) 50.6 (4.2) 0.0153*<br>Time since menopause (n = 313)<br>$\leq 10$ years 80 (66.7) 40 (33.3) <0.001*<br>>10 years 166 (86.0) 27 (14.0)<br>History of fragility fracture<br>No 254 (76.7) 77 (23.3) 0.034*<br>Yes 6 (50.0) 6 (50.0)<br>Family history of fragility fracture (after age of 50 years)<br>No 256 (76.0) 81 (24.0) 0.635 <sup>£</sup><br>Yes 4 (66.7) 2 (33.3)<br>Physical activity<br>No 72 (70.6) 30 (29.4) 0.224<br>Yes, <150 min/week 14 (87.5) 2 (12.5)<br>Yes, >150 min/week 174 (77.3) 51 (22.7)<br>Family history of osteoprosis<br>No 187 (74.5) 64 (25.5) 0.754 <sup>£</sup><br>Unknown 69 (79.3) 18 (20.7)<br>Yes 4 (80.0) 1 (20.0)<br>Chronic disease<br>No 64 (79.0) 17 (21.0) 0.440<br>Yes 196 (74.8) 66 (25.2)<br>Diabetes mellitus<br>No 130 (81.3) 30 (18.8) 0.028*<br>Yes 130 (71.0) 53 (29.0)<br>Hypertension<br>No 123 (70.7) 51 (29.3) 0.025*<br>Yes 38 (74.5) 13 (21.5)<br>Hypothyroidism<br>No 258 (76.1) 81 (23.9) 0.228*<br>Yes 137 (81.1) 32 (18.9)<br>Hypothyroidism<br>No 258 (76.1) 81 (23.9) 0.248<br>Yes 20 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (23.9) 0.248<br>Yes 20 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (23.9) 0.248<br>Yes 20 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (23.9) 0.248<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (23.9) 0.248<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (23.9) 0.248<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (25.5) 0.041*<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (25.5) 0.041*<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (25.7) 0.498<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 258 (75.1) 81 (25.7) 0.498<br>Yes 127 (77.4) 37 (22.6)<br>Thyroxine<br>No 133 (74.3) 46 (25.7) 0.498<br>Yes 127 (77.4) 37 (22.6)<br>Thyroxine<br>No 133 (74.3) 46 (25.7) 0.498<br>Yes 30 (75.9) 70 (24.1) 0.883<br>Yes 39 (75.0) 13 (25.0)<br>Yitamin D<br>No 179 (74.6) 61 (25.4) 0.421<br>Yes 31 (75.6) 70 (24.1) 0.421<br>Yes 31 (75.6) 70 (24.1) 0.421<br>Yes 31 (75.6) 70 (24.1) 0.421<br>Yes 31 | Mean (SD)                          | 62.1 (7.6) | 58.5 (6.7)               | $< 0.001^{*}$              |
| Mean (SD)31.4 (5.8) $34.2$ (4.6) $<0.001^*$ MenopauseNo14 (46.7)16 (53.3) $<0.001^*$ Yes246 (78.6)67 (21.4)Age at menopause (n = 313)Mean (SD)49.8 (3.0)50.6 (4.2) $0.0153^*$ Time since menopause (n = 313) $\leq 10$ years166 (86.0)27 (14.0)History of fragility fractureNo254 (76.7)77 (23.3) $0.034^*$ Yes6 (50.0)6 (50.0)Family history of fragility fracture (after age of 50 years)No $256$ (76.0)81 (24.0) $0.635^t$ Yes4 (66.7)2 (33.3)Physical activityNo72 (70.6) $30$ (29.4) $0.224$ Yes, <150 min/week   | BMI                                |            |                          | 0.004*                     |
| No14 (46.7)16 (53.3)<0.001*Yes246 (78.6)67 (21.4)Age at menopause (n = 313)  | Mean (SD)                          | 31.4 (5.8) | 34.2 (4.6)               | < 0.001*                   |
| No       14 (40.7)       10 (35.3) $<$ (300)         Yes       246 (78.6)       67 (21.4)         Age at menopause (n = 313) $<$ $<$ Sime since menopause (n = 313) $<$ $<$ $<$ $\leq$ 10 years       80 (66.7)       40 (33.3) $<$ $<$ $>$ 10 years       166 (86.0)       27 (14.0) $<$ History of fragility fracture $<$ $<$ $<$ $<$ No       254 (76.7)       77 (23.3) $<$ $<$ $<$ Partial history of fragility fracture (after age of 50 years) $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$  | Menopause                          | 14 (46 7)  | 16 (52.2)                | <0.001*                    |
| The (1000) of (21.11)Age at menopause (n = 313)(0.0153*)Mean (SD)49.8 (3.0)50.6 (4.2)0.0153*Time since menopause (n = 313)(0.013.3)<0.001*   | Yes                                | 246 (78.6) | 67(214)                  | < 0.001                    |
| Mean (SD)49.8 (3.0)50.6 (4.2)0.0153*Mean (SD)49.8 (3.0)50.6 (4.2)0.0153*Time since menopause (n = 313) $\leq 10$ years80 (66.7)40 (33.3) $< 0.001^*$ >10 years166 (86.0)27 (14.0)14.0)History of fragility fractureNo254 (76.7)77 (23.3)0.034*Yes6 (50.0)6 (50.0)6 (50.0)Family history of fragility fracture (after age of 50 years)No256 (76.0)81 (24.0)0.635 <sup>£</sup> Yes4 (66.7)2 (33.3)2(2.4)0.224Yes, <150 min/week  | Age at menopause $(n = 3)$         | 13)        | 07 (2111)                |                            |
| Time since menopause (n = 313)<br>$\leq 10$ years 80 (66.7) 40 (33.3) <0.001*<br>>10 years 166 (86.0) 27 (14.0)<br>History of fragility fracture<br>No 254 (76.7) 77 (23.3) 0.034*<br>Yes 6 (50.0) 6 (50.0)<br>Family history of fragility fracture (after age of 50 years)<br>No 256 (76.0) 81 (24.0) 0.635 <sup>¢</sup><br>Yes 4 (66.7) 2 (33.3)<br>Physical activity<br>No 72 (70.6) 30 (29.4) 0.224<br>Yes, <150 min/week 14 (87.5) 2 (12.5)<br>Yes, >150 min/week 174 (77.3) 51 (22.7)<br>Family history of osteoporosis<br>No 187 (74.5) 64 (25.5) 0.754 <sup>¢</sup><br>Unknown 69 (79.3) 18 (20.7)<br>Yes 4 (80.0) 1 (20.0)<br>Chronic disease<br>No 64 (79.0) 17 (21.0) 0.440<br>Yes 196 (74.8) 66 (25.2)<br>Diabetes mellitus<br>No 130 (81.3) 30 (18.8) 0.028*<br>Yes 196 (74.8) 66 (25.2)<br>Diabetes mellitus<br>No 130 (81.3) 30 (18.8) 0.028*<br>Yes 137 (81.1) 32 (18.9)<br>Hypetthyroidism<br>No 222 (76.0) 70 (24.0) 0.815<br>Yes 38 (74.5) 13 (25.5)<br>Hypetthyroidism<br>No 258 (76.1) 81 (23.9) 0.248<br>Yes 2 (50.0) (50.0)<br>Oral hypoglycemic<br>No 140 (80.5) 34 (19.5) 0.041*<br>Yes 120 (71.0) 49 (29.0)<br>Insulin<br>No 243 (75.9) 77 (24.1) 0.827<br>Yes 17 (73.9) 6 (26.1)<br>Antihypertensive<br>No 133 (74.3) 46 (25.7) 0.498<br>Yes 127 (77.4) 37 (22.6)<br>Thyroxine<br>No 221 (75.9) 70 (24.1) 0.883<br>Yes 39 (75.0) 13 (25.0)<br>Vitamin D<br>No 179 (74.6) 61 (25.4) 0.421<br>Yes 81 (78.6) 22 (21.4)  | Mean (SD)                          | 49.8 (3.0) | 50.6 (4.2)               | 0.0153*                    |
|  | Time since menopause (n            | = 313)     |                          |                            |
| >10 years 166 (86.0) 27 (14.0)       History of fragility fracture       No 254 (76.7) 77 (23.3) 0.034*       Yes 6 (50.0) 6 (50.0)       Family history of fragility fracture (after age of 50 years)       No 256 (76.0) 81 (24.0) 0.635£       Yes 4 (66.7) 2 (33.3)       Physical activity       No 72 (70.6) 30 (29.4) 0.224       Yes, <150 min/week 174 (77.3) 51 (22.7)       Family history of osteoporosis       No 187 (74.5) 64 (25.5) 0.754£       Unknown 69 (79.3) 18 (20.7)       Yes 4 (80.0) 1 (20.0)       Chronic disease       No 64 (79.0) 17 (21.0) 0.440       Yes 196 (74.8) 66 (25.2)       Diabetes mellitus       No 130 (81.3) 30 (18.8) 0.028*       Yes 130 (71.0) 53 (29.0)       Hypertension       No 123 (70.7) 51 (29.3) 0.025*       Yes 130 (71.0) 53 (29.0)       Hypertension       No 123 (70.7) 51 (29.3) 0.025*       Yes 38 (74.5) 13 (25.5)       Hyperthyroidism       No 222 (76.0) 70 (24.0) 0.815       Yes 38 (74.5) 13 (25.5)       Hyperthyroidism       No 258 (76.1) 81 (23.9) 0.248       Yes 2 (20.0) (50.0)       Crail hypoglycemic       No 243 (75.9) 77 (24.1) 0.827       Yes 120 (71.0) 49 (29.0)       Insulin       No 243 (75.9) 77 (24.1) 0.827       Yes 120 (71.0) 49 (29.0)       Insulin       No 243 (75.9) 77 (24.1) 0.827       Yes 120 (71.0) 49 (29.0)       Insulin       No 243 (75.9) 77 (24.1) 0.827       Yes 120 (71.0) 49 (29.0)       Insulin       No 133 (74.3) 46 (25.7) 0.498       Yes 120 (71.0) 49 (29.0)       Insulin       No 133 (74.3) 46 (25.7) 0.498       Yes 127 (77.4) 37 (22.6)       Thyroxine       No 133 (74.3) 46 (25.7) 0.498       Yes 21 (75.9) 70 (24.1) 0.883       Yes 39 (75.0) 13 (25.0)       Vitamin D       No 179 (74.6) 61 (25.4) 0.421       Yes 117 (75.6) 61 (25.4) 0.421       Yes 117 (  | $\leq 10$ years                    | 80 (66.7)  | 40 (33.3)                | $< 0.001^{*}$              |
| History of fragility fractureNo $254 (76.7)$ $77 (23.3)$ $0.034^*$ Yes $6 (50.0)$ $6 (50.0)$ $81 (24.0)$ $0.635^{\pounds}$ Samuely history of fragilityfracture (after age of 50 years)No $256 (76.0)$ $81 (24.0)$ $0.635^{\pounds}$ Yes $4 (66.7)$ $2 (33.3)$ $23.3)$ Physical activity $2 (23.3)$ $23.3)$ Physical activity $72 (70.6)$ $30 (29.4)$ $0.224$ $256 (76.0)$ $81 (24.0)$ $0.224$ Yes, <150 min/week  | >10 years                          | 166 (86.0) | 27 (14.0)                |                            |
| No $254 (76.7)$ $77 (23.3)$ $0.034^*$ Yes $6 (50.0)$ $6 (50.0)$ Family history of fragility fracture (after age of 50 years)No $2256 (76.0)$ $81 (24.0)$ $0.635^{\pounds}$ Yes $4 (66.7)$ $2 (33.3)$ Physical activityNo $72 (70.6)$ $30 (29.4)$ $0.224$ Yes, <150 min/week  | History of fragility fractur       | e          | /                        |                            |
| Yes $6 (30.0)$ $6 (30.0)$ Family history of fragility fracture (after age of 50 years)No $256 (76.0)$ No $256 (76.0)$ Yes $4 (66.7)$ Yes $4 (66.7)$ 2 (33.3)Physical activityNo $72 (70.6)$ No $2 (33.3)$ Physical activityNo $72 (70.6)$ No $12 (2.5)$ Yes, <150 min/week   | No                                 | 254 (76.7) | 77 (23.3)                | 0.034*                     |
| Painity instity of fragminy fracture (after age of 30 years)No256 (76.0) $81 (24.0)$ $0.635^{\pounds}$ Yes4 (66.7)2 (33.3)Physical activityNo72 (70.6) $30 (29.4)$ $0.224$ Yes, <150 min/week  | Yes<br>Family history of fragility | 6 (50.0)   | 6(50.0)                  |                            |
| No2.50 (10.0)61 (24.0)0.053Yes4 (66.7)2 (33.3)Physical activity $No$ 72 (70.6)30 (29.4)0.224Yes, <150 min/week   | No                                 | 256(760)   | $^{\circ}$ age of 50 yea | (18)<br>0.635 <sup>£</sup> |
| Physical activityNo72 (70.6)30 (29.4)0.224Yes, <150 min/week   | Yes                                | 4 (66 7)   | 2(33.3)                  | 0.055                      |
| No72 (70.6) $30 (29.4)$ $0.224$ Yes, <150 min/week   | Physical activity                  | 1 (00.7)   | 2 (55.5)                 |                            |
| Yes, <150 min/week14 (87.5)2 (12.5)Yes, >150 min/week174 (77.3)51 (22.7)Family history of osteoporosisNo187 (74.5)64 (25.5) $0.754^{\pounds}$ Unknown69 (79.3)18 (20.7)Yes4 (80.0)1 (20.0)Chronic diseaseNo64 (79.0)17 (21.0) $0.440$ Yes196 (74.8)66 (25.2)0.130 (81.3)30 (18.8) $0.028^*$ Yes130 (81.3)30 (18.8) $0.028^*$ Yes130 (71.0)53 (29.0)HypertensionNo123 (70.7)51 (29.3) $0.025^*$ Yes137 (81.1)32 (18.9)HypothyroidismNo222 (76.0)70 (24.0) $0.815$ Yes38 (74.5)13 (25.5)HyperthyroidismNo258 (76.1)81 (23.9) $0.248$ Yes2 (50.0)(50.0)Oral hypoglycemicNo243 (75.9)77 (24.1) $0.827$ Yes120 (71.0)49 (29.0)InsulinNo243 (75.9)77 (24.1) $0.827$ Yes127 (77.4)37 (22.6)ThyroxineNo133 (74.3)46 (25.7) $0.498$ Yes127 (77.4)37 (22.6)No221 (75.9)70 (24.1) $0.883$ Yes39 (75.0)13 (25.0)Vitamin DNo221 (75.9)70 (24.1) $0.883$ Yes39 (75.0)13 (25.0)   | No                                 | 72 (70.6)  | 30 (29.4)                | 0.224                      |
| Yes, >150 min/week174 (77.3)51 (22.7)Family history of osteoporosisNo $187 (74.5)$ $64 (25.5)$ $0.754^{\pounds}$ Unknown $69 (79.3)$ $18 (20.7)$ Yes $4 (80.0)$ $1 (20.0)$ Chronic diseaseNo $64 (79.0)$ $17 (21.0)$ $0.440$ Yes $196 (74.8)$ $66 (25.2)$ Diabetes mellitusNo $130 (81.3)$ $30 (18.8)$ $0.028^*$ Yes $130 (71.0)$ $53 (29.0)$ HypertensionNo $123 (70.7)$ $51 (29.3)$ $0.025^*$ Yes $137 (81.1)$ $32 (18.9)$ HypothyroidismNo $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ HyperthyroidismNo $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ Ordel*Oral hypoglycemicNo $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ InsulinNo $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $127 (77.4)$ $37 (22.6)$ ThyroxineNo $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $179 (74.6)$ $61 (25.4)$ $0.421$   | Yes, <150 min/week                 | 14 (87.5)  | 2 (12.5)                 |                            |
| Family history of osteoporosisNo $187 (74.5)$ $64 (25.5)$ $0.754^{\pounds}$ Unknown $69 (79.3)$ $18 (20.7)$ Yes $4 (80.0)$ $1 (20.0)$ Chronic disease $No$ $64 (79.0)$ $17 (21.0)$ $0.440$ Yes $196 (74.8)$ $66 (25.2)$ Diabetes mellitus $No$ $130 (81.3)$ $30 (18.8)$ $0.028^*$ Yes $130 (71.0)$ $53 (29.0)$ Hypertension $No$ $123 (70.7)$ $51 (29.3)$ $0.025^*$ Yes $137 (81.1)$ $32 (18.9)$ Hypothyroidism $No$ $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ Hyperthyroidism $No$ $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ $110 (19.0)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ $110 (19.0)$ $0.827$ Yes $120 (71.0)$ $49 (29.0)$ $110 (19.0)$ $0.827$ Yes $120 (71.0)$ $49 (29.0)$ $110 (19.0)$ $110 (19.0)$ Insulin $No$ $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ $110 (25.0)$ Vitamin D $No$ $129 (75.0)$ $13 (25.0)$ Vitamin D $No$ $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$ $0.421$   | Yes, >150 min/week                 | 174 (77.3) | 51 (22.7)                |                            |
| No $187 (74.5)$ $64 (25.5)$ $0.754^{L}$ Unknown $69 (79.3)$ $18 (20.7)$ Yes $4 (80.0)$ $1 (20.0)$ Chronic disease $No$ $64 (79.0)$ $17 (21.0)$ $0.440$ Yes $196 (74.8)$ $66 (25.2)$ $0.28^{*}$ Diabetes mellitus $No$ $130 (81.3)$ $30 (18.8)$ $0.028^{*}$ Yes $130 (81.3)$ $30 (18.8)$ $0.028^{*}$ Yes $130 (71.0)$ $53 (29.0)$ $Hypertension$ No $123 (70.7)$ $51 (29.3)$ $0.025^{*}$ Yes $137 (81.1)$ $32 (18.9)$ $Hypethyroidism$ No $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ $Hyperthyroidism$ No $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ $0.041^{*}$ Yes $120 (71.0)$ $49 (29.0)$ $118ulin$ No $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ $133 (74.3)$ $46 (25.7)$ Antihypertensive $No$ $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ $75.0$ $13 (25.0)$ Vitamin D $No$ $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$ $1421$   | Family history of osteopor         | rosis      |                          | c                          |
| Unknown $69 (79.3)$ $18 (20.7)$ Yes $4 (80.0)$ $1 (20.0)$ Chronic disease $No$ $64 (79.0)$ $17 (21.0)$ $0.440$ Yes $196 (74.8)$ $66 (25.2)$ $0.28*$ Diabetes mellitus $No$ $130 (81.3)$ $30 (18.8)$ $0.028*$ Yes $130 (71.0)$ $53 (29.0)$ $Hypertension$ No $123 (70.7)$ $51 (29.3)$ $0.025*$ Yes $137 (81.1)$ $32 (18.9)$ $Hypothyroidism$ No $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ $Hyperthyroidism$ No $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ $0.041*$ Yes $120 (71.0)$ $49 (29.0)$ $118ulin$ No $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ $133 (74.3)$ $46 (25.7)$ Antihypertensive $No$ $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ $71 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ $13 (25.0)$ Vitamin D $No$ $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$ $22 (21.4)$  | No                                 | 187 (74.5) | 64 (25.5)                | 0.754 <sup>±</sup>         |
| Yes $4 (80.0)$ $1 (20.0)$ Chronic disease $No$ $64 (79.0)$ $17 (21.0)$ $0.440$ Yes $196 (74.8)$ $66 (25.2)$ $0.28*$ Diabetes mellitus $No$ $130 (81.3)$ $30 (18.8)$ $0.028*$ Yes $130 (71.0)$ $53 (29.0)$ $0.025*$ $Yes$ Yes $130 (71.0)$ $53 (29.0)$ $0.025*$ Hypertension $No$ $123 (70.7)$ $51 (29.3)$ $0.025*$ Yes $137 (81.1)$ $32 (18.9)$ $0.025*$ Hypothyroidism $No$ $222 (76.0)$ $70 (24.0)$ $0.815$ No $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ $0.041*$ No $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $120 (71.0)$ $49 (29.0)$ $0.041*$ Yes $120 (71.0)$ $49 (29.0)$ $0.041*$ Yes $120 (71.0)$ $49 (29.0)$ $0.041*$ No $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ $0.498$ Yes $39 (75.0)$ $13 (25.0)$ $0.421$ No $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$ $0.421$  | Unknown                            | 69 (79.3)  | 18 (20.7)                |                            |
| No $64 (79.0)$ $17 (21.0)$ $0.440$ Yes $196 (74.8)$ $66 (25.2)$ Diabetes mellitusNo $130 (81.3)$ $30 (18.8)$ $0.028^*$ Yes $130 (71.0)$ $53 (29.0)$ HypertensionNo $123 (70.7)$ $51 (29.3)$ $0.025^*$ Yes $137 (81.1)$ $32 (18.9)$ HypothyroidismNo $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ HyperthyroidismNo $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ Oral hypoglycemicNo $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ InsulinNo $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $127 (77.4)$ $37 (22.6)$ ThyroxineNo $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$  | Chronic disease                    | 4 (80.0)   | 1 (20.0)                 |                            |
| No196 (74.8)66 (25.2)Diabetes mellitus130 (81.3)30 (18.8) $0.028^*$ No130 (81.3)30 (18.8) $0.028^*$ Yes130 (71.0)53 (29.0)HypertensionNo123 (70.7)51 (29.3) $0.025^*$ Yes137 (81.1)32 (18.9)HypothyroidismNo222 (76.0)70 (24.0) $0.815$ Yes38 (74.5)13 (25.5)HyperthyroidismNo258 (76.1)81 (23.9) $0.248$ Yes2 (50.0)(50.0)00011*Oral hypoglycemicNo140 (80.5)34 (19.5) $0.041^*$ Yes120 (71.0)49 (29.0)InsulinNo243 (75.9)77 (24.1) $0.827$ Yes17 (73.9)6 (26.1)AntihypertensiveNo133 (74.3)46 (25.7) $0.498$ Yes127 (77.4)37 (22.6)ThyroxineNo221 (75.9)70 (24.1) $0.883$ Yes39 (75.0)13 (25.0)Vitamin DNo179 (74.6)61 (25.4) $0.421$ Yes81 (78.6)22 (21.4) $0.421$  | No                                 | 64 (79.0)  | 17 (21.0)                | 0 440                      |
| Diabetes mellitusIf $V(M_{0})$ If $V(M_{0})$ If $V(M_{0})$ No130 (81.3)30 (18.8) $0.028^{*}$ Yes130 (71.0)53 (29.0)HypertensionNo123 (70.7)51 (29.3) $0.025^{*}$ Yes137 (81.1)32 (18.9)HypothyroidismNo222 (76.0)70 (24.0) $0.815$ Yes38 (74.5)13 (25.5)HyperthyroidismNo258 (76.1)81 (23.9) $0.248$ Yes2 (50.0)(50.0)000Oral hypoglycemicNo140 (80.5)34 (19.5) $0.041^{*}$ Yes120 (71.0)49 (29.0)118InsulinNo243 (75.9)77 (24.1) $0.827$ Yes17 (73.9)6 (26.1)133 (74.3)46 (25.7) $0.498$ Yes127 (77.4)37 (22.6)71 $0.883$ Yes39 (75.0)13 (25.0) $0.421$ $0.883$ Yes39 (75.0)13 (25.0) $0.421$ Yes81 (78.6)22 (21.4) $0.421$   | Yes                                | 196 (74.8) | 66 (25.2)                | 0.110                      |
| No $130 (81.3)$ $30 (18.8)$ $0.028^*$ Yes $130 (71.0)$ $53 (29.0)$ HypertensionNo $123 (70.7)$ $51 (29.3)$ $0.025^*$ Yes $137 (81.1)$ $32 (18.9)$ HypothyroidismNo $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ HyperthyroidismNo $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ Oral hypoglycemicNo $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ InsulinNo $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ AntihypertensiveNo $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ ThyroxineNo $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $179 (74.6) 61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$  | Diabetes mellitus                  |            | ,                        |                            |
| Yes130 (71.0)53 (29.0)Hypertension $123 (70.7)$ 51 (29.3) $0.025^*$ Yes137 (81.1)32 (18.9) $0.025^*$ Hypothyroidism $137 (81.1)$ 32 (18.9)No222 (76.0)70 (24.0) $0.815$ Yes38 (74.5)13 (25.5)Hyperthyroidism $130 (71.0)$ $81 (23.9)$ $0.248$ Yes2 (50.0)(50.0)Oral hypoglycemic $0.000 (50.0)$ No140 (80.5)34 (19.5) $0.041^*$ Yes120 (71.0)49 (29.0)Insulin $0.243 (75.9)$ 77 (24.1) $0.827$ Yes17 (73.9)6 (26.1)Antihypertensive $0.433 (74.3)$ 46 (25.7) $0.498$ Yes127 (77.4)37 (22.6)Thyroxine $0.221 (75.9)$ 70 (24.1) $0.883$ Yes39 (75.0)13 (25.0) $0.421$ No179 (74.6)61 (25.4) $0.421$ Yes $0.179 (74.6)$ 61 (25.4) $0.421$   | No                                 | 130 (81.3) | 30 (18.8)                | 0.028*                     |
| HypertensionNo123 (70.7)51 (29.3) $0.025^*$ Yes137 (81.1)32 (18.9)HypothyroidismNo222 (76.0)70 (24.0) $0.815$ Yes38 (74.5)13 (25.5)HyperthyroidismNo258 (76.1)81 (23.9) $0.248$ Yes2 (50.0)(50.0)Oral hypoglycemicNo140 (80.5)34 (19.5) $0.041^*$ Yes120 (71.0)49 (29.0)InsulinNo243 (75.9)77 (24.1) $0.827$ Yes17 (73.9)6 (26.1)AntihypertensiveNo133 (74.3)46 (25.7) $0.498$ Yes127 (77.4)37 (22.6)ThyroxineNo221 (75.9)70 (24.1) $0.883$ Yes39 (75.0)13 (25.0)Vitamin DNo179 (74.6)61 (25.4) $0.421$ Yes81 (78.6)22 (21.4)  | Yes                                | 130 (71.0) | 53 (29.0)                |                            |
| No $123 (70.7)$ $51 (29.3)$ $0.025^*$ Yes $137 (81.1)$ $32 (18.9)$ HypothyroidismNo $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ HyperthyroidismNo $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ Oral hypoglycemicNo $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ InsulinNo $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ AntihypertensiveNo $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ ThyroxineNo $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$   | Hypertension                       |            |                          |                            |
| Yes $137 (81.1)$ $32 (18.9)$ HypothyroidismNo $222 (76.0)$ $70 (24.0)$ $0.815$ Yes $38 (74.5)$ $13 (25.5)$ HyperthyroidismNo $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ Oral hypoglycemicNo $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ InsulinNo $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ AntihypertensiveNo $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ ThyroxineNo $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$   | No                                 | 123 (70.7) | 51 (29.3)                | 0.025*                     |
| Hypothyroidism       222 (76.0)       70 (24.0)       0.815         Yes       38 (74.5)       13 (25.5)         Hyperthyroidism  | Yes                                | 137 (81.1) | 32 (18.9)                |                            |
| No $222 (70.0)$ $70 (24.0)$ $0.613$ Yes $38 (74.5)$ $13 (25.5)$ HyperthyroidismNo $258 (76.1)$ $81 (23.9)$ $0.248$ Yes $2 (50.0)$ $(50.0)$ Oral hypoglycemicNo $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ InsulinNo $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ AntihypertensiveNo $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ ThyroxineNo $221 (75.9)$ $70 (24.1)$ $0.883$ Yes $39 (75.0)$ $13 (25.0)$ Vitamin DNo $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$  | Hypothyroidism                     | 222 (76.0) | 70 (24 0)                | 0.915                      |
| Hyperthyroidism       56 (74.5)       15 (25.5)         Hyperthyroidism       56 (74.5)       15 (25.5)         No       258 (76.1)       81 (23.9)       0.248         Yes       2 (50.0)       (50.0)       0         Oral hypoglycemic       0.00       140 (80.5)       34 (19.5)       0.041*         Yes       120 (71.0)       49 (29.0)       0       0.827         Insulin       0.827       798       17 (73.9)       6 (26.1)         Antihypertensive       0.404       0.827       0.498         Yes       127 (77.4)       37 (22.6)       0.498         Thyroxine       0.821 (75.9)       70 (24.1)       0.883         Yes       39 (75.0)       13 (25.0)       0.421         Vitamin D       0.00       179 (74.6)       61 (25.4)       0.421         Yes       81 (78.6)       22 (21.4)       0.421  | INU<br>Ves                         | 222(70.0)  | 70(24.0)<br>13(25.5)     | 0.815                      |
| No       258 (76.1)       81 (23.9)       0.248         Yes       2 (50.0)       (50.0)         Oral hypoglycemic  | Hyperthyroidism                    | 30 (74.3)  | 15 (25.5)                |                            |
| Yes $2 (50.0)$ $(50.0)$ Oral hypoglycemic140 (80.5) $34 (19.5)$ $0.041^*$ No140 (80.5) $34 (19.5)$ $0.041^*$ Yes120 (71.0) $49 (29.0)$ Insulin $0.243 (75.9)$ $77 (24.1)$ $0.827$ Yes17 (73.9) $6 (26.1)$ Antihypertensive $0.498$ No133 (74.3) $46 (25.7)$ $0.498$ Yes127 (77.4) $37 (22.6)$ Thyroxine $0.221 (75.9)$ $70 (24.1)$ $0.883$ Yes39 (75.0) $13 (25.0)$ $0.421$ Vitamin D $0.9 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$ $0.421$   | No                                 | 258 (76.1) | 81 (23.9)                | 0.248                      |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$  | Yes                                | 2 (50.0)   | (50.0)                   |                            |
| No $140 (80.5)$ $34 (19.5)$ $0.041^*$ Yes $120 (71.0)$ $49 (29.0)$ Insulin $120 (71.0)$ $49 (29.0)$ No $243 (75.9)$ $77 (24.1)$ $0.827$ Yes $17 (73.9)$ $6 (26.1)$ Antihypertensive $133 (74.3)$ $46 (25.7)$ $0.498$ Yes $127 (77.4)$ $37 (22.6)$ Thyroxine $139 (75.0)$ $13 (25.0)$ Vitamin D $179 (74.6)$ $61 (25.4)$ $0.421$ Yes $81 (78.6)$ $22 (21.4)$  | Oral hypoglycemic                  |            |                          |                            |
| Yes       120 (71.0)       49 (29.0)         Insulin   | No                                 | 140 (80.5) | 34 (19.5)                | 0.041*                     |
| Insulin       No       243 (75.9)       77 (24.1)       0.827         Yes       17 (73.9)       6 (26.1)       0.498         Antihypertensive       133 (74.3)       46 (25.7)       0.498         Yes       127 (77.4)       37 (22.6)       0.498         Thyroxine       39 (75.0)       13 (25.0)       0.883         Yes       39 (75.0)       13 (25.0)       0.421         Vitamin D       179 (74.6)       61 (25.4)       0.421         Yes       81 (78.6)       22 (21.4)       0.421   | Yes                                | 120 (71.0) | 49 (29.0)                |                            |
| No       243 (75.9)       77 (24.1)       0.827         Yes       17 (73.9)       6 (26.1)         Antihypertensive         No       133 (74.3)       46 (25.7)       0.498         Yes       127 (77.4)       37 (22.6)         Thyroxine   | Insulin                            | 242 (75.0) | 77 (24.1)                | 0.027                      |
| Yes       17 (75.9)       6 (26.1)         Antihypertensive       133 (74.3)       46 (25.7)       0.498         Yes       127 (77.4)       37 (22.6)         Thyroxine       221 (75.9)       70 (24.1)       0.883         Yes       39 (75.0)       13 (25.0)         Vitamin D       179 (74.6)       61 (25.4)       0.421         Yes       81 (78.6)       22 (21.4)  | No<br>Var                          | 243 (75.9) | 77(24.1)                 | 0.827                      |
| No       133 (74.3)       46 (25.7)       0.498         Yes       127 (77.4)       37 (22.6)         Thyroxine   | 1 cs<br>Antihypertensive           | 17 (75.9)  | 0 (20.1)                 |                            |
| Yes       127 (77.4)       37 (22.6)         Thyroxine       221 (75.9)       70 (24.1)       0.883         Yes       39 (75.0)       13 (25.0)         Vitamin D       179 (74.6)       61 (25.4)       0.421         Yes       81 (78.6)       22 (21.4)   | No                                 | 133 (74-3) | 46 (25.7)                | 0 498                      |
| Thyroxine         221 (75.9)         70 (24.1)         0.883           Yes         39 (75.0)         13 (25.0)           Vitamin D         179 (74.6)         61 (25.4)         0.421           Yes         81 (78.6)         22 (21.4)         0.421  | Yes                                | 127 (77.4) | 37 (22.6)                | 0.190                      |
| No         221 (75.9)         70 (24.1)         0.883           Yes         39 (75.0)         13 (25.0)           Vitamin D         179 (74.6)         61 (25.4)         0.421           Yes         81 (78.6)         22 (21.4)         0.421   | Thyroxine                          | (.,,       | ()                       |                            |
| Yes     39 (75.0)     13 (25.0)       Vitamin D     179 (74.6)     61 (25.4)     0.421       Yes     81 (78.6)     22 (21.4)   | No                                 | 221 (75.9) | 70 (24.1)                | 0.883                      |
| No         179 (74.6)         61 (25.4)         0.421           Yes         81 (78.6)         22 (21.4)  | Yes                                | 39 (75.0)  | 13 (25.0)                |                            |
| No179 (74.6)61 (25.4)0.421Yes81 (78.6)22 (21.4)  | Vitamin D                          |            |                          |                            |
| Yes 81 (78.6) 22 (21.4)  | No                                 | 179 (74.6) | 61 (25.4)                | 0.421                      |
|  | Yes                                | 81 (78.6)  | 22 (21.4)                |                            |

(continued on next page)

#### Table 3 (continued)

| Variables      | BMD<br>disorder<br>present<br>n (%) | BMD<br>disorder<br>absent<br>n (%) | p-value |
|----------------|-------------------------------------|------------------------------------|---------|
| Calcium        |                                     |                                    |         |
| No             | 205 (73.5)                          | 74 (26.5)                          | 0.036*  |
| Yes            | 55 (85.9)                           | 9 (14.1)                           |         |
| PPIs           |                                     |                                    |         |
| No             | 200 (74.1)                          | 25.9 (70)                          | 0.151   |
| Yes            | 60 (82.2)                           | 13 (17.8)                          |         |
| Oral cortisone |                                     |                                    |         |
| No             | 258 (75.7)                          | 83 (24.3)                          | 1.000*  |
| Yes            | 2 (100)                             | 0 (0.0)                            |         |
|                |                                     |                                    |         |

 $p < 0.05 \mbox{ was considered statistically significant.}$ 

\*Significant p-value.

<sup>£</sup>Fisher exact p-value.

association of menopause with BMD disorders, as the prevalence of BMD disorders was 78.6% compared to 46.7% among non-menopausal women. BMD disorders were significantly more frequent among participants with hypertension 81% versus 70.7% among those without hypertension. On the other hand, DM was associated with a lower prevalence of 71% compared to 81% among non-diabetics.

Table 4: Multivariate logistic regression analysis of factors associated with the presence of BMD disorders among women visiting a DEXA scanning center in Buraidah, KSA (n = 343).

| Variables               | Adjusted OR (95% CI) | P-value     |
|-------------------------|----------------------|-------------|
| Age§                    | 1.04 (0.99-1.09)     | 0.090       |
| <b>BMI</b> <sup>§</sup> | 0.93 (0.88-0.97)     | 0.003*      |
| Menopause               |                      |             |
| No                      | 1                    | $0.009^{*}$ |
| Yes                     | 3.76 (1.39-10.14)    |             |
| History of fragilit     | y fracture           |             |
| No                      | 1                    | 0.034*      |
| Yes                     | 0.26 (0.07-0.90)     |             |
| Hypertension            |                      |             |
| No                      | 1                    | 0.035*      |
| Yes                     | 1.91 (1.05-3.47)     |             |
| Hyperthyroidism         |                      |             |
| No                      | 1                    | 0.121       |
| Yes                     | 0.20 (0.03-1.53)     |             |
| Oral hypoglycemi        | ic                   |             |
| No                      | 1                    | < 0.001*    |
| Yes                     | 0.31 (0.17-0.57)     |             |
| Thyroxine               |                      |             |
| No                      | 1                    | 0.276       |
| Yes                     | 0.65 (0.30-1.41)     |             |
| Calcium                 |                      |             |
| No                      | 1                    | 0.008*      |
| Yes                     | 3.22 (1.35-7.68)     |             |
| PPIs                    |                      |             |
| No                      | 1                    | 0.165       |
| Yes                     | 1.70 (0.80-3.59)     |             |

p < 0.05 was considered statistically significant. <sup>§</sup>Continuous variable.

\*Significant p-value.

#### Predictors of BMD disorders

Logistics regression analysis showed that increasing BMI has protective effects on BMD disorders (adjusted OR 0.93, 95% CI: 0.88-0.97). Women who had reached menopause had a higher odds of BMD disorders (adjusted OR 3.76, 95% CI: 1.39-10.14) compared to non-menopausal women. Similarly, compared to normotensives, those with hypertension had a higher odds of BMD disorders (adjusted OR 1.91, 95% CI: 1.05-3.47). Use of oral hypoglycemics was associated with lower odds of BMD disorders (adjusted OR 0.31, 95% CI: 0.17-0.57) compared to no use of these agents (Table 4).

# Discussion

To the best of my knowledge, this is the first study from the Qassim region of KSA. The BMD disorders were found to be highly prevalent in Saudi women. The spine was most commonly affected by the BMD disorders. Osteoporosis was lower in the femur compared to the spine. The factors significantly associated with BMD disorders were age, BMI, menopause, hypertension, oral hypoglycemics, and calcium supplementation.

The prevalence of BMD disorders in this study was 76%, which is higher than that reported from Riyadh 58.5%.<sup>13</sup> A high prevalence of BMD disorders was found in the current study, which was conducted in a DEXA referral center, whereas the community-based study by Al Quaiz et al.<sup>13</sup> reported a lower prevalence. However, another study from Riyadh in a similar setting reported a prevalence of BMD disorders of 63%.<sup>18</sup> Other hospital-based studies from KSA have reported a comparable prevalence of BMD disorders among women such as Taif 71%<sup>12</sup> and Arar 68%.<sup>11</sup>

The prevalence of osteoporosis in this study was 34%, which was slightly higher than that reported from Riyadh where the prevalence among women visiting the DEXA scanning center was 30%.<sup>18</sup> On the other hand, the prevalence of osteoporosis was found to be lower in Taif  $26\%^{12}$  and Arar  $18\%^{11}$  The current estimate is however similar to the 34% reported in a previous systematic review of studies in KSA.9 Osteopenia alone was observed in 42% of the women. This result is similar to a study conducted in Arar 40% and comparable to studies from Taif 45%<sup>12</sup> and Riyadh 36%.<sup>18</sup> Studies from other Arab countries have also reported a varying prevalence of osteoporosis and osteopenia. A study from Syria reported a prevalence of osteoporosis of 24%, which is lower than this study, whereas osteopenia was comparable 45%.<sup>19</sup> A study from United Arab Emirates also showed a prevalence of osteoporosis and osteopenia of 26% and 36%, respectively<sup>20</sup> whereas in Jordan, the prevalence was 35% and 47%, respectively.<sup>21</sup> These variations in the prevalence of BMD disorders may be due to the differences of settings in which the study was conducted (population- versus institution-based), the population (pre-menopausal versus post-menopausal), social, cultural, and dietary patterns.<sup>22,23</sup> As aforementioned, there are alternative explanations for differences in the prevalence of BMD disorders across various regions of KSA, but these needs to be verified through large-scale studies using standardized tools and comparable populations. The presence of such differences would require tailored arrangements for the prevention and management of BMD disorders in the regional context.

Spines are more frequently affected by BMD disorders than the femur.<sup>12,21,24</sup> This study also found that spines had a higher prevalence of BMD disorders compared to the femur. Furthermore, osteoporosis was higher in spines, 31% compared to the femur, 9.0% and 13.1% left and right femurs respectively. A consistent pattern was reported in a study from KSA<sup>12</sup> and Kuwait.<sup>24</sup> Subsequently osteopenia was higher in the femur, which is consistent with a previous study.<sup>21</sup> These differences in the involvement of different skeletal sites could be due to differences in age at which bone mass is achieved at different skeletal sites.<sup>25</sup>

This study found that increasing BMI was associated with a lower risk of osteoporosis. This finding is consistent with the results of another study conducted in KSA and other settings. where increasing BMI was associated with lower risk of osteoporosis.<sup>26–28</sup> Although not fully understood, the negative association of BMI with BMD disorders has been attributed to increased bone mass due to mechanical load caused by heavy weight among obese and increased production of estrogen in adipose tissues which suppresses osteoclasts leading to increased bone density.<sup>29,30</sup> Menopause has been found to be associated with a higher prevalence of BMD disorders, which is consistent with other studies.<sup>31,32</sup> Menopause causes a reduction in estrogen levels, which results in excessive bone loss along with linear bone loss with aging. This calls for clinicians to screen menopausal women for BMD disorders and fragility fracture risks.

Oral hypoglycemics are associated with a lower risk of BMD disorders. The literature on the association of DM with osteoporosis is not conclusive as there are discrepant findings across studies and type of diabetes.<sup>33-35</sup> Some studies have shown that oral hypoglycemic agents are associated with a lower risk of BMD disorders.<sup>36,37</sup> Studies have also shown that various hypoglycemic agents affect bone metabolism differently. Metformin activates rabbit muscle pyruvate kinase, which results in the differentiation and mineralization of osteoblasts, leading to increased BMD. Thiazolidinediones have been found to activate osteoclasts.<sup>38</sup> Due to the unavailability of data on a specific type of oral hypoglycemic used by study participants, the exact inference about the observed association may not be possible. Nonetheless, metformin is first-line medication for DM in KSA.

On the other hand, hypertension is associated with a higher risk of BMD disorders. Evidence suggests that low BMD and hypertension have a strong association.<sup>39,40</sup> It is postulated that high blood pressure causes loss of calcium in urine, which results in loss of bone mass.<sup>41</sup>

This study adds to the scarce literature on the epidemiology of BMD disorders in KSA. The DEXA scan was used to ascertain BMD and the diagnosis of osteoporosis, which is the gold standard. There are certain limitations that need to be considered while interpreting the results of this study. This study was conducted in a referral center that may overestimate the prevalence of BMD disorders, as the referred patients were at high risk of BMD disorders. This would also affect its generalizability to the general population. Another limitation is that we did not use a standardized tool to measure physical activity, which may have also affected the estimation of physical activity in this study. Finally, the associations reported in this paper should be interpreted cautiously as the sample may not have been powered enough to accurately measure the associations. Nonetheless, the results provide a basis for further exploration of risk factors of low BMD among women.

# Conclusion

A high prevalence of BMD was found among women in this study. This necessitates strengthening the osteoporosis program in the country to prevent negative health and economic consequences of BMD disorders in the country. In addition, large community-based studies are recommended to establish an accurate burden of the osteoporosis in order to tailor the health care services for these disorders among women.

## Source of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## **Conflict of interest**

The author has no conflict of interest to declare.

# Ethical approval

This study was reviewed and approved by Qassim Regional Bioethics Committee (Approval No. 607-43-3136, date: 18-04-2020).

## Consent

Informed consent was obtained from all participants before collecting the data.

## Acknowledgment

Researcher is thankful to the management of the DEXA Center, Buraidah for granting permission to collect the data.

#### References

- Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006; 194(2): S3-S11.
- 2. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization; 1994.
- Alejandro P, Constantinescu F. A review of osteoporosis in the older adult: an update. Rheum Dis Clin 2018; 44(3): 437–451.
- Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 2013; 8(1): 1–115.
- Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17(12): 1726–1733.

- 6. World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report; 2007.
- Sànchez-Riera L, Carnahan E, Vos T, Veerman L, Norman R, Lim SS, et al. The global burden attributable to low bone mineral density. Ann Rheum Dis 2014; 73(9): 1635–1645. https://doi.org/10.1136/annrheumdis-2013-204320.
- Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosisrelated fractures in the United States, 2005–2025. J Bone Miner Res 2007; 22(3): 465–475.
- Sadat-Ali M, Al-Habdan IM, Al-Turki HA, Azam MQ. An epidemiological analysis of the incidence of osteoporosis and osteoporosis-related fractures among the Saudi Arabian population. Ann Saudi Med 2012; 32(6): 637–641. <u>https://doi.org/</u> 10.5144/0256-4947.2012.637.
- Ali AMB, Abdullah AMR, Alsayed AMM, Alotaibi RJ, Alharbi MNF, Alanazi MFM, et al. Osteoporosis: a common health problem in senior adult population of Arar City, Saudi Arabia. Egypt J Hosp Med 2018; 72(7): 4894–4897.
- Oommen A, AlZahrani I. Prevalence of osteoporosis and factors associated with osteoporosis in women above 40 years in the Northern Part of Saudi Arabia. Int J Res Med Sci 2014; 2(1): 274.
- Abdulaziz AA, Hendi OM, Abdelbaky A, Alzaidi SA, Abdulaziz GA, Abdulaziz RA. Prevalence and risk factors of osteoporosis in women aged above 60 years at Taif governorate, Saudi Arabia. Indo Am J Pharm Sci 2019; 6(1): 773–780.
- AlQuaiz AM, Kazi A, Tayel S, Shaikh SA, Al-Sharif A, Othman S, et al. Prevalence and factors associated with low bone mineral density in Saudi women: a community based survey. BMC Musculoskelet Disord 2014; 15: 5. <u>https://doi.org/</u> 10.1186/1471-2474-15-5.
- 14. Aziziyeh R, Garcia Perlaza J, Saleem N, Sadat-Ali M, Elsalmawy A, McTavish RK, et al. The burden of osteoporosis in Saudi Arabia: a scorecard and economic model. J Med Econ 2020; 23(7): 767–775.
- Riggs BL, Melton III LJ. Involutional osteoporosis. N Engl J Med 1986; 314(26): 1676–1686.
- 16. Zeidan ZA, Sultan IE, Guraya SS, Al-Zalabani AH, Khoshhal KI. Low bone mineral density among young healthy adult Saudi women. Prevalence and associated factors in the age group of 20 to 36 years. Saudi Med J 2016; 37(11): 1225–1233. https://doi.org/10.15537/smj.2016.11.16248.
- Chin K-Y, Ima-Nirwana S. Sex steroids and bone health status in men. Int J Endocrinol 2012; 2012.
- Gouhar GK, Tamimm REM, Alhemaidi WW, AlAbdulwahed NB, Alharbi KK, Qattan AY, et al. Association of specific risk factors for osteoporosis in Saudi female patients referred for DEXA scan in Riyadh City. Int J Med Dev Ctries 2019; 3(4): 353–357. https://doi.org/10.24911/IJMDC.51-1545568941.
- Hijazi N, Alourfi Z. Association between hypertension, antihypertensive drugs, and osteoporosis in postmenopausal Syrian women: a cross-sectional study. Adv Med 2020; 2020:7014212. https://doi.org/10.1155/2020/7014212.
- Fawzy T, Muttappallymyalil J, Sreedharan J, Ahmed A, Alshamsi SOS, Al Ali MS, et al. Association between body mass index and bone mineral density in patients referred for dual-energy X-ray absorptiometry scan in Ajman, UAE. J Osteoporos 2011; 2011:876309. <u>https://doi.org/10.4061/2011/ 876309</u>.
- Hyassat D, Alyan T, Jaddou H, Ajlouni K. Prevalence and risk factors of osteoporosis among Jordanian postmenopausal women attending the National Center for Diabetes, Endocrinology and Genetics in Jordan. Biores Open Access 2017; 6(1): 85–93.

- Muñoz-Garach A, García-Fontana B, Muñoz-Torres M. Nutrients and dietary patterns related to osteoporosis. Nutrients 2020; 12(7): 1986.
- 23. Borba-Pinheiro CJ, Drigo AJ, de Alencar Carvalho MC, da Silva NS, Dantas EH. Factors that contribute to low bone density in postmenopausal women in different amazonian communities. Ther Adv Musculoskelet Dis 2011; 3(2): 81–90. https://doi.org/10.1177/1759720x11401674.
- Mahussain S, Badr H, Al-Zaabi K, Mohammad M, Alnafisi N. Bone mineral density in healthy Kuwaiti women. Arch Osteoporos 2006; 1(1): 51–57.
- 25. Iki M, Kagamimori S, Kagawa Y, Matsuzaki T, Yoneshima H, Marumo F. Bone mineral density of the spine, hip and distal forearm in representative samples of the Japanese female population: Japanese Population-Based Osteoporosis (JPOS) Study. **Osteoporos Int 2001**; 12(7): 529–537.
- 26. Al-Homood IA, Sheshah I, Mohammed AGA, Gasim GI. The prevalence and risk factors of osteoporosis among a Saudi female diabetic population. Open Access Maced J Med Sci 2017; 5(2): 177.
- 27. Guney E, Kisakol G, Ozgen G, Yilmaz C, Yilmaz R, Kabalak T. Effect of weight loss on bone metabolism: comparison of vertical banded gastroplasty and medical intervention. **Obes Surg 2003**; 13(3): 383–388.
- 28. Radak TL. Caloric restriction and calcium's effect on bone metabolism and body composition in overweight and obese premenopausal women. Nutr Rev 2004; 62(12): 468–481.
- 29. Kameda T, Mano H, Yuasa T, Mori Y, Miyazawa K, Shiokawa M, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997; 186(4): 489–495.
- Zhao L-J, Liu Y-J, Liu P-Y, Hamilton J, Recker RR, Deng H-W. Relationship of obesity with osteoporosis. J Clin Endocrinol Metab 2007; 92(5): 1640–1646.
- Kritz-Silverstein D, Barrett-Connor E. Early menopause, number of reproductive years, and bone mineral density in postmenopausal women. Am J Public Health 1993; 83(7): 983– 988.
- 32. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93(3): 861–868.
- Piepkorn B, Kann P, Forst T, Andreas J, Pfützner A, Beyer J. Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997; 29(11): 584–591.
- 34. Weinstock RS, Goland RS, Shane E, Clemens TL, Lindsay R, Bilezikian JP. Bone mineral density in women with type II diabetes mellitus. J Bone Miner Res 1989; 4(1): 97–101.
- Strotmeyer ES, Cauley JA. Diabetes mellitus, bone mineral density, and fracture risk. Curr Opin Endocrinol Diabetes Obes 2007; 14(6): 429–435.
- Ahmed MEAM, Alenezi EZM, Alanazi ASS, Alanazi AMR, Alanazi WSG, Alanazi AMM, et al. Osteoporosis in women in the Kingdom of Saudi Arabia: a review article. Int J Med Dev Ctries 2020; 4(2): 441–447. <u>https://doi.org/10.24911/IJMDC.</u> 51-1577051457.
- 37. Tseng C-H. Metformin use is associated with a lower risk of osteoporosis/vertebral fracture in Taiwanese patients with type 2 diabetes mellitus. Eur J Endocrinol 2021; 184(2): 299–310.
- Gilbert M, Pratley R. The impact of diabetes treatments on bone health in patients with type 2 diabetes mellitus. Endocr Rev 2015; 36(2): 194–213.
- Ye Z, Lu H, Liu P. Association between essential hypertension and bone mineral density: a systematic review and meta-analysis. Oncotarget 2017; 8(40): 68916–68927. <u>https://doi.org/</u> <u>10.18632/oncotarget.20325</u>.

- 40. Yarema N, Kotsiuba O, Krytskyy T, Marushchak M, Krynytska I. Peculiarities of arterial hypertension in postmenopausal women with bone mineral density disorders and dyslipidemia. Pol Merkur Lekarski 2020; 48(283): 5–9.
- **41.** Cappuccio FP, Kalaitzidis R, Duneclift S, Eastwood JB. Unravelling the links between calcium excretion, salt intake, hypertension, kidney stones and bone metabolism. **J Nephrol 2000**; 13(3): 169–177.

**How to cite this article**: Aldukhayel A. Prevalence and patterns of bone mineral density disorders among women in Buraidah, KSA. J Taibah Univ Med Sc 2023;18(2):348–355.